Kabra Drugs Expansion

Conclusion: Execution Risk: The investment is purely at the LOI stage and subject to definitive site sign-offs and regulatory milestones. Capital Sourcing Risk: Kabra has a micro-cap capitalization 56 Cr. Funding a ₹200 Cr project will require significant equity dilution or debt leverage, though softened by the stated 60% government subsidy/incentive context. Financial Impact Timeline: Benefits will not impact the Profit & Loss statement immediately. Initial capital outflows will sit in Capital Work-in-Progress (CWIP) through FY27 and FY28. Earnings impact will begin reflecting around FY 2028-29. Market Alignment: The market is currently underestimating the structural pivot. The company is trading at a low historical multiplier on its newly scaled trading earnings, but the structural change to an asset-heavy manufacturer with massive state incentives could dramatically re-rate its equity value over the next 3 years. Final VIEW: Positive While execution and dilution risks are prominent given the disparity between the company's current balance sheet size and the size of the project, the massive 60% incentive support package from the Chhattisgarh state government turns this into a highly transformative corporate expansion roadmap.